RxDoctor Payments DataLook up a doctor →

Allan Levey, PhD

Neurology · Atlanta, GANPI 1740398494

Payments from drug & device makers

$4,151,267in general payments, 2019–2025

Across 436 payments — averaging $9521.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2M
  • Eisai Inc.$975K
  • Novartis$483K
  • Roche Diagnostics Corporation$357K
  • Genentech, Inc.$351K
  • Eli Lilly$11K
  • plus $13K from 4 others

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen16$1,961,450
Eisai Inc.355$975,216
Novartis6$483,227
Roche Diagnostics Corporation1$356,518
Genentech, Inc.41$351,167
Eli Lilly6$10,588
Takeda Pharmaceuticals U.S.A., Inc.5$6,495
Novo Nordisk2$3,900
Merck2$2,562
Lilly USA, LLC2$144

How this compares

$4,151,267 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$7,101
Medicare patients
33
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →